Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schwarz Omeprazole Strategy, Part 2: DTC Ads, No Further Price Cuts

Executive Summary

Schwarz is giving generic omeprazole a marketing push into the broader proton pump inhibitor category rather than reducing price to further capture Prilosec's share in the omeprazole segment
Advertisement

Related Content

Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market
Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market
Generic Omeprazole Ads Debut; Schwarz Offers $10 Rebate For Copays
Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold
AstraZeneca Retains 90% Of GI Business Despite Prilosec Generics
AstraZeneca Retains 90% Of GI Business Despite Prilosec Generics
Schwarz Omeprazole On Track For $1 Bil.; Transforming Event For Company?
Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm
Advertisement
UsernamePublicRestriction

Register

PS042256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel